CryoCell International Inc (CCEL) - Net Assets
Based on the latest financial reports, CryoCell International Inc (CCEL) has net assets worth $-14.83 Million USD as of August 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.17 Million) and total liabilities ($78.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CCEL asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.83 Million |
| % of Total Assets | -23.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 213.4 |
CryoCell International Inc - Net Assets Trend (1996–2024)
This chart illustrates how CryoCell International Inc's net assets have evolved over time, based on quarterly financial data. Also explore CryoCell International Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for CryoCell International Inc (1996–2024)
The table below shows the annual net assets of CryoCell International Inc from 1996 to 2024. For live valuation and market cap data, see CryoCell International Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $-13.22 Million | -19.81% |
| 2023-11-30 | $-11.03 Million | -623.69% |
| 2022-11-30 | $-1.52 Million | -136.43% |
| 2021-11-30 | $4.18 Million | +257.00% |
| 2020-11-30 | $-2.67 Million | +61.67% |
| 2019-11-30 | $-6.95 Million | +21.95% |
| 2018-11-30 | $-8.91 Million | +28.75% |
| 2017-11-30 | $-12.50 Million | +18.89% |
| 2016-11-30 | $-15.41 Million | -210.51% |
| 2015-11-30 | $-4.96 Million | +53.72% |
| 2014-11-30 | $-10.73 Million | -15.74% |
| 2013-11-30 | $-9.27 Million | -3.00% |
| 2012-11-30 | $-9.00 Million | -265.71% |
| 2011-11-30 | $-2.46 Million | -58.68% |
| 2010-11-30 | $-1.55 Million | +70.07% |
| 2009-11-30 | $-5.18 Million | +25.76% |
| 2008-11-30 | $-6.98 Million | -5.88% |
| 2007-11-30 | $-6.59 Million | -215.02% |
| 2006-11-30 | $-2.09 Million | -630.25% |
| 2005-11-30 | $394.56K | +147.21% |
| 2004-11-30 | $-835.75K | +77.95% |
| 2003-11-30 | $-3.79 Million | -138.42% |
| 2002-11-30 | $9.87 Million | -32.05% |
| 2001-11-30 | $14.52 Million | +118.84% |
| 2000-11-30 | $6.64 Million | +32.71% |
| 1999-11-30 | $5.00 Million | +117.39% |
| 1998-11-30 | $2.30 Million | -25.81% |
| 1997-11-30 | $3.10 Million | -16.22% |
| 1996-11-30 | $3.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CryoCell International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2987762600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $148.70K | % |
| Other Components | $19.41 Million | % |
| Total Equity | $-13.22 Million | 100.00% |
CryoCell International Inc Competitors by Market Cap
The table below lists competitors of CryoCell International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Paru Co. Ltd
KQ:043200
|
$27.39 Million |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
$27.39 Million |
|
Hudson Acquisition I Corp. Common Stock
NASDAQ:HUDA
|
$27.39 Million |
|
Beam Global
NASDAQ:BEEM
|
$27.40 Million |
|
Synergetic Auto Performance Public Company Limited
BK:ASAP
|
$27.38 Million |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
$27.36 Million |
|
Falcon Power Co Ltd
TW:1516
|
$27.35 Million |
|
Anteotech Ltd
AU:ADO
|
$27.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CryoCell International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,031,232 to -13,216,017, a change of -2,184,785.
- Net income of 402,095 contributed positively to equity growth.
- Dividend payments of 2,020,539 reduced retained earnings.
- Share repurchases of 1,423,871 reduced equity.
- Other factors increased equity by 857,530.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $402.10K | +3.04% |
| Dividends Paid | $2.02 Million | -15.29% |
| Share Repurchases | $1.42 Million | -10.77% |
| Other Changes | $857.53K | +6.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CryoCell International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-11-30 | $0.52 | $3.45 | x |
| 1997-11-30 | $0.45 | $3.45 | x |
| 1998-11-30 | $0.32 | $3.45 | x |
| 1999-11-30 | $0.61 | $3.45 | x |
| 2000-11-30 | $0.68 | $3.45 | x |
| 2001-11-30 | $1.37 | $3.45 | x |
| 2002-11-30 | $0.84 | $3.45 | x |
| 2003-11-30 | $-0.33 | $3.45 | x |
| 2004-11-30 | $-0.07 | $3.45 | x |
| 2005-11-30 | $0.03 | $3.45 | x |
| 2006-11-30 | $-0.18 | $3.45 | x |
| 2007-11-30 | $-0.57 | $3.45 | x |
| 2008-11-30 | $-0.60 | $3.45 | x |
| 2009-11-30 | $-0.44 | $3.45 | x |
| 2010-11-30 | $-0.13 | $3.45 | x |
| 2011-11-30 | $-0.21 | $3.45 | x |
| 2012-11-30 | $-0.80 | $3.45 | x |
| 2013-11-30 | $-0.84 | $3.45 | x |
| 2014-11-30 | $-1.03 | $3.45 | x |
| 2015-11-30 | $-0.51 | $3.45 | x |
| 2016-11-30 | $-1.90 | $3.45 | x |
| 2017-11-30 | $-1.63 | $3.45 | x |
| 2018-11-30 | $-1.19 | $3.45 | x |
| 2019-11-30 | $-0.83 | $3.45 | x |
| 2020-11-30 | $-0.33 | $3.45 | x |
| 2021-11-30 | $0.50 | $3.45 | x |
| 2022-11-30 | $-0.18 | $3.45 | x |
| 2023-11-30 | $-1.32 | $3.45 | x |
| 2024-11-30 | $-1.61 | $3.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CryoCell International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.26%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (3.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 16.22% | 22.22% | 0.64x | 1.14x | $230.00K |
| 1997 | -51.61% | -400.00% | 0.10x | 1.29x | $-1.91 Million |
| 1998 | -100.00% | -766.67% | 0.07x | 1.78x | $-2.53 Million |
| 1999 | -12.00% | -35.29% | 0.31x | 1.10x | $-1.10 Million |
| 2000 | -22.46% | -70.67% | 0.26x | 1.24x | $-2.15 Million |
| 2001 | 6.20% | 15.93% | 0.32x | 1.20x | $-552.49K |
| 2002 | -55.67% | -75.32% | 0.51x | 1.45x | $-6.28 Million |
| 2003 | 0.00% | -99.63% | 1.05x | 0.00x | $-7.14 Million |
| 2004 | 0.00% | 23.26% | 1.05x | 0.00x | $2.92 Million |
| 2005 | 261.92% | 7.15% | 1.02x | 36.07x | $993.95K |
| 2006 | 0.00% | -16.36% | 1.17x | 0.00x | $-2.60 Million |
| 2007 | 0.00% | -28.67% | 1.50x | 0.00x | $-4.35 Million |
| 2008 | 0.00% | -4.40% | 1.57x | 0.00x | $-62.57K |
| 2009 | 0.00% | 8.73% | 1.12x | 0.00x | $1.94 Million |
| 2010 | 0.00% | 19.34% | 0.97x | 0.00x | $3.57 Million |
| 2011 | 0.00% | -11.69% | 0.92x | 0.00x | $-1.85 Million |
| 2012 | 0.00% | -35.11% | 1.46x | 0.00x | $-5.41 Million |
| 2013 | 0.00% | 0.14% | 1.65x | 0.00x | $954.23K |
| 2014 | 0.00% | 2.75% | 1.97x | 0.00x | $1.63 Million |
| 2015 | 0.00% | 38.43% | 1.08x | 0.00x | $8.60 Million |
| 2016 | 0.00% | -5.71% | 1.18x | 0.00x | $220.63K |
| 2017 | 0.00% | 9.12% | 1.06x | 0.00x | $3.57 Million |
| 2018 | 0.00% | -2.93% | 0.69x | 0.00x | $36.01K |
| 2019 | 0.00% | 7.20% | 0.74x | 0.00x | $2.99 Million |
| 2020 | 0.00% | 11.64% | 0.67x | 0.00x | $3.89 Million |
| 2021 | 49.79% | 7.21% | 0.48x | 14.50x | $1.67 Million |
| 2022 | 0.00% | 9.14% | 0.47x | 0.00x | $2.92 Million |
| 2023 | 0.00% | -30.38% | 0.51x | 0.00x | $-8.42 Million |
| 2024 | 0.00% | 1.26% | 0.49x | 0.00x | $1.72 Million |
Industry Comparison
This section compares CryoCell International Inc's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $523,195,409
- Average return on equity (ROE) among peers: 19.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CryoCell International Inc (CCEL) | $-14.83 Million | 16.22% | N/A | $27.39 Million |
| Acadia Healthcare Company Inc (ACHC) | $2.57 Billion | 7.77% | 1.50x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $80.57 Million | 4.47% | 1.00x | $1.84 Billion |
| agilon health Inc (AGL) | $1.04 Billion | -10.24% | 0.63x | $264.44 Million |
| Airsculpt Technologies Inc (AIRS) | $123.68 Million | 6.13% | 0.45x | $136.11 Million |
| Amedisys Inc (AMED) | $3.37 Million | 159.63% | 13.12x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $562.53 Million | 23.56% | 1.23x | $624.22 Million |
| American Shared Hospital Service (AMS) | $26.28 Million | 2.32% | 0.83x | $13.33 Million |
| American Oncology Network Inc. (AONC) | $62.02 Million | 4.17% | 4.26x | $263.24 Million |
| Ardent Health Partners, Inc. (ARDT) | $760.28 Million | -4.69% | 2.12x | $1.29 Billion |
| Astrana Health Inc (ASTH) | $-240.91K | 0.00% | 0.00x | $1.57 Billion |
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manu… Read more